Guiding Your Drug Name to Approval
Did you know that, despite the industry’s best efforts, more than 40% of the proposed brand names submitted to FDA and EMEA are rejected? Securing regulatory approval for a new brand name is often a difficult hurdle for companies to overcome.
A Center for Business Intelligence webinar will be addressing this issue on 16 September at 1 pm EDT. Also to be discussed are the recent changes at FDA and the pending initiation of a new Pilot Program to evaluate brand names.
The presenter, InterbrandHealth's John Breen, will be sharing insights on what market research will be recommended for proposed brand name submissions to the FDA going forward. To register for and participate in the one-hour session to address the proactive steps bio/pharma companies can undertake to mitigate the brand name challenge, click here.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety